tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TCRX Stock Latest News

TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
The FlyTScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
4d ago
TCRX
TScan Therapeutics Reports Increased Revenue Amid Rising Losses
PremiumCompany Announcements
TScan Therapeutics Reports Increased Revenue Amid Rising Losses
5d ago
TCRX
TScan Therapeutics: Strategic Focus and Financial Stability Drive Buy Rating
PremiumRatings
TScan Therapeutics: Strategic Focus and Financial Stability Drive Buy Rating
6d ago
TCRX
Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics
PremiumRatings
Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics
6d ago
TCRX
TScan Therapeutics reports Q3 EPS (28c), consensus (33c)
PremiumThe Fly
TScan Therapeutics reports Q3 EPS (28c), consensus (33c)
6d ago
TCRX
TScan Therapeutics downgraded to Neutral from Buy at BTIG
PremiumThe FlyTScan Therapeutics downgraded to Neutral from Buy at BTIG
14d ago
TCRX
TScan Therapeutics downgraded to Neutral from Buy at BTIG
Premium
The Fly
TScan Therapeutics downgraded to Neutral from Buy at BTIG
14d ago
TCRX
TScan Therapeutics price target lowered to $6 from $9 at Needham
Premium
The Fly
TScan Therapeutics price target lowered to $6 from $9 at Needham
15d ago
TCRX
TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program
PremiumRatings
TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program
15d ago
TCRX
TScan Therapeutics Shifts Focus to Hematologic Malignancies
PremiumCompany Announcements
TScan Therapeutics Shifts Focus to Hematologic Malignancies
15d ago
8K
TCRX
TScan Therapeutics to reduce workforce by 30%
PremiumThe Fly
TScan Therapeutics to reduce workforce by 30%
15d ago
TCRX
TScan Therapeutics’ Innovative Cancer Study: A Potential Game-Changer for Solid Tumors
PremiumCompany Announcements
TScan Therapeutics’ Innovative Cancer Study: A Potential Game-Changer for Solid Tumors
22d ago
TCRX
TScan Therapeutics’ Long-Term Study: A Closer Look at TCR-T Therapies
PremiumCompany AnnouncementsTScan Therapeutics’ Long-Term Study: A Closer Look at TCR-T Therapies
22d ago
TCRX
TScan Therapeutics Advances Cancer Research with New Screening Study
Premium
Company Announcements
TScan Therapeutics Advances Cancer Research with New Screening Study
22d ago
TCRX
TScan Therapeutics’ Innovative Study on TSC-100 and TSC-101: A Potential Game-Changer in Leukemia Treatment
Premium
Company Announcements
TScan Therapeutics’ Innovative Study on TSC-100 and TSC-101: A Potential Game-Changer in Leukemia Treatment
22d ago
TCRX
TScan Therapeutics Updates Corporate Milestones and Strategies
PremiumCompany Announcements
TScan Therapeutics Updates Corporate Milestones and Strategies
2M ago
8K
TCRX
TScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy Rating
PremiumRatings
TScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy Rating
3M ago
TCRX
Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to ‘Buy’ Rating
PremiumRatings
Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to ‘Buy’ Rating
3M ago
TCRX
TScan Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
TScan Therapeutics Reports Q2 2025 Financial Results
3M ago
TCRX
TScan Therapeutics reports Q2 EPS (28c), consensus (32c)
PremiumThe FlyTScan Therapeutics reports Q2 EPS (28c), consensus (32c)
3M ago
TCRX
TScan Therapeutics expects cash to fund operations into Q1 of 2027
Premium
The Fly
TScan Therapeutics expects cash to fund operations into Q1 of 2027
3M ago
TCRX
TCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
TCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
TCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >